Taysha Gene begins key corporate period with patient trial data and FDA update plans in 2027

Taysha Gene Therapies reported its Q3 2026 results and confirmed key corporate updates, including the ongoing well-tolerated status of its TSHA-102 treatments and a 2027 timeline for regulatory feedback. For investors, the company is now preparing to initiate a next-generation CNS gene therapy franchise.